Results 171 to 180 of about 5,903 (227)
Some of the next articles are maybe not open access.
Fluoropyrimidine-induced cardiotoxicity
Critical Reviews in Oncology/Hematology, 2018Fluoropyrimidines (5-fluorouracil and capecitabine) are antimetabolite drugs, widely used for the treatment of a variety of cancers, both in adjuvant and in metastatic setting. Although the most common toxicities of these drugs have been extensively studied, robust data and comprehensive characterization still lack concerning fluoropyrimidine-induced ...
Ilaria, Depetris +6 more
openaire +3 more sources
Capillary electrophoresis of fluoropyrimidines
Journal of High Resolution Chromatography, 1991Frank David
exaly +2 more sources
Fluoropyrimidine-Associated Cardiotoxicity
Cardiology Clinics, 2019Fluoropyrimidines are chemotherapeutic agents that confer great benefit to many patients with solid tumors, but their use is often limited by cardiotoxicity. The incidence and precise mechanisms of cardiotoxicity remain uncertain. Clinical presentations of fluoropyrimidine toxicity are varied and include chest pain, myocardial infarction, acute ...
Jaya, Kanduri +3 more
openaire +2 more sources
Fluoropyrimidines: A Critical Evaluation
Oncology, 1999After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer. A range of 5-FU treatment regimens with or without biochemical modulation are currently used and toxicity appears to be schedule dependent.
R A, Brito +6 more
openaire +2 more sources
Fluoropyrimidine resistance in colon cancer
Expert Review of Anticancer Therapy, 2002A significant obstacle for the management of patients with colorectal cancer is intrinsic drug resistance or in patients that respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms. These include alterations in drug influx, drug efflux, intracellular metabolic activation, intracellular catabolism ...
Richard, Gorlick, Debabrata, Banerjee
openaire +2 more sources
THE SYNTHESIS OF 5-FLUOROPYRIMIDINES
Journal of the American Chemical Society, 1957Charles Heidelberger
exaly +2 more sources
Fluoropyrimidine-associated cardiotoxicity: revisited
Expert Opinion on Drug Safety, 2009The syndrome of 5-fluorouracil (5-FU)-associated cardiotoxicity remains poorly defined.We performed a literature review (1969 - 2007) and compiled data derived from 377 evaluable cases out of 448 reported cases.Patient age ranged from 14 to 86 years. Of the patients 65% were 55 years old and the male:female ratio was 1.5:1.
M Wasif, Saif +2 more
openaire +2 more sources
Modulation of fluoropyrimidine metabolism by chlorpromazine
Biochemical and Biophysical Research Communications, 1986Chlorpromazine is a potent inhibitor of calmodulin and can alter the accumulation, metabolism, and incorporation into RNA of several fluoropyrimidine drugs. Using S-180 murine sarcoma cells, the accumulation of the base Fluorouracil and its metabolism to ribonucleotides is enhanced by chlorpromazine treatment, as measured by HPLC.
A, Tseng, M, Brooks, E, Cadman
openaire +2 more sources
Oral Fluoropyrimidines in Cancer Treatment
Cancer Investigation, 2000(2000). Oral Fluoropyrimidines in Cancer Treatment. Cancer Investigation: Vol. 18, No. 8, pp. 747-760.
N L, Lewis, N J, Meropol
openaire +2 more sources
American Journal of Clinical Oncology: Cancer Clinical Trials, 1999
Patient preferences, quality of life issues, and economic considerations are driving the development of orally administered chemotherapy. Oral fluorinated pyrimidines, which have been used in Japan, are attracting increasing interest as a means to provide convenient, less toxic treatment without compromising efficacy. The oral fluoropyrimidines provide
openaire +2 more sources
Patient preferences, quality of life issues, and economic considerations are driving the development of orally administered chemotherapy. Oral fluorinated pyrimidines, which have been used in Japan, are attracting increasing interest as a means to provide convenient, less toxic treatment without compromising efficacy. The oral fluoropyrimidines provide
openaire +2 more sources